파이프라인
| Platform | Project | Theraqeutics | Indication | R&D | Preclinical | Phase I | Phase II | NDA |
|---|---|---|---|---|---|---|---|---|
| TIL | NEOG-100 | TIL | Solid tumor (TNBC, NSCLC) |
|
||||
| TIL | NEOG-200 | TIL-LAK | Solid tumor |
|
||||
| TIL | NEOG-300 | NeoAg-TIL | Solid tumor |
|
||||
| TCR-T | NEOG-400 | Private NeoAg-TCR-T | Solid tumor |
|
-
NEOG-100
-
Theraqeutics
TIL -
Indication
Solid tumor (TNBC, NSCLC)
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-200
-
Theraqeutics
TIL-LAK -
Indication
Solid tumor
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-300
-
Theraqeutics
NeoAg-TIL -
Indication
Solid tumor
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-400
-
Theraqeutics
Private NeoAg-TCR-T -
Indication
Solid tumor
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-